S&P 500   5,123.17 (-1.46%)
DOW   37,993.79 (-1.21%)
QQQ   438.63 (-1.51%)
AAPL   175.32 (+0.16%)
MSFT   422.42 (-1.29%)
META   514.35 (-1.68%)
GOOGL   158.15 (-0.79%)
AMZN   185.92 (-1.66%)
TSLA   171.61 (-1.71%)
NVDA   887.23 (-2.09%)
AMD   163.79 (-3.94%)
NIO   4.11 (-7.85%)
BABA   72.07 (-3.71%)
T   16.38 (-0.24%)
F   12.66 (-2.91%)
MU   123.48 (-3.16%)
GE   154.20 (-2.03%)
CGC   7.99 (-1.96%)
DIS   114.36 (-2.38%)
AMC   2.70 (-3.57%)
PFE   26.04 (-1.14%)
PYPL   64.87 (-1.41%)
XOM   121.64 (-0.12%)
S&P 500   5,123.17 (-1.46%)
DOW   37,993.79 (-1.21%)
QQQ   438.63 (-1.51%)
AAPL   175.32 (+0.16%)
MSFT   422.42 (-1.29%)
META   514.35 (-1.68%)
GOOGL   158.15 (-0.79%)
AMZN   185.92 (-1.66%)
TSLA   171.61 (-1.71%)
NVDA   887.23 (-2.09%)
AMD   163.79 (-3.94%)
NIO   4.11 (-7.85%)
BABA   72.07 (-3.71%)
T   16.38 (-0.24%)
F   12.66 (-2.91%)
MU   123.48 (-3.16%)
GE   154.20 (-2.03%)
CGC   7.99 (-1.96%)
DIS   114.36 (-2.38%)
AMC   2.70 (-3.57%)
PFE   26.04 (-1.14%)
PYPL   64.87 (-1.41%)
XOM   121.64 (-0.12%)
S&P 500   5,123.17 (-1.46%)
DOW   37,993.79 (-1.21%)
QQQ   438.63 (-1.51%)
AAPL   175.32 (+0.16%)
MSFT   422.42 (-1.29%)
META   514.35 (-1.68%)
GOOGL   158.15 (-0.79%)
AMZN   185.92 (-1.66%)
TSLA   171.61 (-1.71%)
NVDA   887.23 (-2.09%)
AMD   163.79 (-3.94%)
NIO   4.11 (-7.85%)
BABA   72.07 (-3.71%)
T   16.38 (-0.24%)
F   12.66 (-2.91%)
MU   123.48 (-3.16%)
GE   154.20 (-2.03%)
CGC   7.99 (-1.96%)
DIS   114.36 (-2.38%)
AMC   2.70 (-3.57%)
PFE   26.04 (-1.14%)
PYPL   64.87 (-1.41%)
XOM   121.64 (-0.12%)
S&P 500   5,123.17 (-1.46%)
DOW   37,993.79 (-1.21%)
QQQ   438.63 (-1.51%)
AAPL   175.32 (+0.16%)
MSFT   422.42 (-1.29%)
META   514.35 (-1.68%)
GOOGL   158.15 (-0.79%)
AMZN   185.92 (-1.66%)
TSLA   171.61 (-1.71%)
NVDA   887.23 (-2.09%)
AMD   163.79 (-3.94%)
NIO   4.11 (-7.85%)
BABA   72.07 (-3.71%)
T   16.38 (-0.24%)
F   12.66 (-2.91%)
MU   123.48 (-3.16%)
GE   154.20 (-2.03%)
CGC   7.99 (-1.96%)
DIS   114.36 (-2.38%)
AMC   2.70 (-3.57%)
PFE   26.04 (-1.14%)
PYPL   64.87 (-1.41%)
XOM   121.64 (-0.12%)
NASDAQ:PAVM

PAVmed (PAVM) Stock Price, News & Analysis

$1.99
-0.01 (-0.50%)
(As of 12:25 PM ET)
Today's Range
$1.91
$2.04
50-Day Range
$1.68
$3.08
52-Week Range
$1.60
$9.36
Volume
17,784 shs
Average Volume
69,116 shs
Market Capitalization
$18.25 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.00

PAVmed MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
976.9% Upside
$21.00 Price Target
Short Interest
Healthy
5.35% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.78
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.43 out of 5 stars

Medical Sector

865th out of 2,784 stocks

Surgical & Medical Instruments Industry

106th out of 285 stocks

PAVM stock logo

About PAVmed Stock (NASDAQ:PAVM)

PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.

PAVM Stock Price History

PAVM Stock News Headlines

PAVmed Inc. (PAVM) Q4 2023 Earnings Call Transcript
Options trading has suddenly become more reliable.
When it hits at a stunning 96% win rate... Options trading has suddenly become more reliable.
Q4 2023 PAVmed Inc Earnings Call
PAVmed Full Year 2023 Earnings: EPS Beats Expectations
What Wall Street expects from PAVmed's earnings
Options trading has suddenly become more reliable.
When it hits at a stunning 96% win rate... Options trading has suddenly become more reliable.
PAVmed Inc PAVM
See More Headlines
Receive PAVM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PAVmed and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/12/2021
Today
4/12/2024
Next Earnings (Estimated)
5/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:PAVM
Fax
N/A
Employees
124
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$21.00
High Stock Price Target
$21.00
Low Stock Price Target
$21.00
Potential Upside/Downside
+950.0%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Net Income
$-64,180,000.00
Net Margins
-2,617.25%
Pretax Margin
-3,232.59%

Debt

Sales & Book Value

Annual Sales
$2.45 million
Book Value
($3.35) per share

Miscellaneous

Free Float
8,016,000
Market Cap
$18.34 million
Optionable
Optionable
Beta
0.85
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Dr. Lishan Aklog M.D. (Age 58)
    Chairman & CEO
    Comp: $945.09k
  • Mr. Dennis M. McGrath CPA (Age 67)
    President, CFO & Corporate Secretary
    Comp: $663.38k
  • Mr. Shaun M. O'Neill M.B.A. (Age 41)
    Executive VP & COO
    Comp: $447.47k
  • Dr. Brian J. deGuzman M.D. (Age 59)
    Executive VP, Chief Technology & Compliance Officer
    Comp: $427.6k
  • Dr. Suman M. Verma M.D.
    Ph.D., Senior VP of Molecular Genetics & Chief Scientific Officer
  • Michael Parks
    Vice President of Investor Relations
  • Mr. Michael Adam Gordon (Age 50)
    Executive VP, General Counsel & Secretary
  • Dr. Deepika A. Lakhani Ph.D.
    Senior VP, Chief Regulatory & Quality Officer
  • Dr. Victoria T. Lee M.D.
    Senior VP & Chief Medical Officer

PAVM Stock Analysis - Frequently Asked Questions

Should I buy or sell PAVmed stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PAVmed in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" PAVM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PAVM, but not buy additional shares or sell existing shares.
View PAVM analyst ratings
or view top-rated stocks.

What is PAVmed's stock price target for 2024?

1 analysts have issued 12 month target prices for PAVmed's stock. Their PAVM share price targets range from $21.00 to $21.00. On average, they expect the company's share price to reach $21.00 in the next twelve months. This suggests a possible upside of 976.9% from the stock's current price.
View analysts price targets for PAVM
or view top-rated stocks among Wall Street analysts.

How have PAVM shares performed in 2024?

PAVmed's stock was trading at $4.12 at the beginning of the year. Since then, PAVM shares have decreased by 52.7% and is now trading at $1.95.
View the best growth stocks for 2024 here
.

When is PAVmed's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 21st 2024.
View our PAVM earnings forecast
.

How were PAVmed's earnings last quarter?

PAVmed Inc. (NASDAQ:PAVM) issued its quarterly earnings data on Thursday, August, 12th. The company reported ($2.10) earnings per share for the quarter, missing the consensus estimate of ($1.50) by $0.60.

When did PAVmed's stock split?

PAVmed's stock reverse split before market open on Thursday, December 7th 2023. The 1-15 reverse split was announced on Thursday, December 7th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, December 7th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of PAVmed own?
How do I buy shares of PAVmed?

Shares of PAVM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PAVM) was last updated on 4/12/2024 by MarketBeat.com Staff

From Our Partners